Senti Biosciences (NASDAQ:SNTI – Get Free Report) and Vericel (NASDAQ:VCEL – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.
Analyst Recommendations
This is a summary of current ratings and target prices for Senti Biosciences and Vericel, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Senti Biosciences | 0 | 0 | 0 | 0 | 0.00 |
| Vericel | 0 | 0 | 7 | 0 | 3.00 |
Vericel has a consensus target price of $57.71, suggesting a potential upside of 6.88%. Given Vericel’s stronger consensus rating and higher probable upside, analysts clearly believe Vericel is more favorable than Senti Biosciences.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Senti Biosciences | $2.56 million | 3.79 | -$71.06 million | ($12.65) | -0.17 |
| Vericel | $197.52 million | 13.40 | -$3.18 million | $0.00 | -5,400,000.00 |
Vericel has higher revenue and earnings than Senti Biosciences. Vericel is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Senti Biosciences and Vericel’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Senti Biosciences | N/A | -84.70% | -48.10% |
| Vericel | 0.37% | 0.35% | 0.22% |
Insider & Institutional Ownership
25.7% of Senti Biosciences shares are owned by institutional investors. 15.9% of Senti Biosciences shares are owned by company insiders. Comparatively, 5.2% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Senti Biosciences has a beta of 2.74, indicating that its stock price is 174% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.
Summary
Vericel beats Senti Biosciences on 10 of the 13 factors compared between the two stocks.
About Senti Biosciences
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
About Vericel
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
